Key facts
- Sandoz has agreed to a $450 million settlement with 43 U.S. states and territories.
- The settlement resolves allegations of anti-competitive conduct in the U.S. generic medicine market.
Sandoz agrees $450 million settlement with 43 US states over antitrust claims
IN SHORT
Swiss drugmaker Sandoz has reached a $450 million settlement with 43 U.S. states and territories to resolve allegations of anti-competitive conduct in the generic medicine market. The agreement includes payments totaling $400 million over seven years starting in 2027, plus an additional $50 million for earlier settlements.
Key Numbers
$450 millionTotal settlement amount
43US states and territories involved
$400 millionPayment over seven years
$50 millionAdditional payment for early settlers
2027Year payments begin
Who's Involved
Sandoz
Swiss generic drugmaker agreeing to settlement
43 U.S. states and territories
Parties to the antitrust litigation settlement
↳ Why This Matters
The settlement resolves significant antitrust claims against Sandoz, potentially averting further legal costs and reputational damage, while also providing financial compensation to states for alleged price-fixing practices in the generic drug market.